chrisvoncsefalvay/vaers-outcomes huggingface dataset:
metallic taste in their mouth after the vaccine; This is a spontaneous report from a contactable pharmacist. This pharmacist reported similar events for two patients. This is the first of two reports.  A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and expiration date not reported), via an unspecified route of administration from an unspecified date at a single dose for Covid-19 immunization.  The patient medical history and concomitant medications were not reported.  The pharmacist reported that she also had 2 other patients who had reported metallic taste in their mouth after the vaccine on an unspecified date. The outcome of the event was unknown.   Information about Lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021026363 same reporter/drug, similar event, different patient;US-PFIZER INC-2021027151 same reporter/drug/event, different patient
Around 7 pm I started feeling a bit nauseous and started having muscle aches. By 8pm I had begun having shaking chills and took my temperature which was 100.2. By 9pm the shaking chills had gotten worse to the point where I felt I couldn't get out of bed and was unable to hold my phone. Around 10pm I took some aspirin.  The shaking and nausea began to improve until I fell asleep around 11pm.  I then woke up feeling generally bad many times until this morning.  This morning I woke up for good around 7am (an hour and a half ago). I'm still pretty achy and have a fever of 100.8 (I have no idea how high it may have gotten between 8pm and now, I had assumed it would be lower now since I feel much better).
Two days after vaccination, the patient experienced some diffuse numbness and tingling from his hips down, felt like getting a muscle cramp. He had no problem walking. On 12/20 he reported having a cold. As of 1/5/10 he still has intermittent pain, stiffness and difficulty in both lower limbs from his hips below. He reports the problems as intermittent and are gradually subsiding.  Follow-up information received - RE: Missing information letter dated 1/21/2010.  Unfortunately, this information is not available to us. When a report of symptoms suggesting a possible adverse event of interest is received, our team attempts to contact the reporting individual - provided that permission to contact has been granted. We have contacted this patient and he or she has aggreed to share his or her contact information with VAERS. Pt phone number and e-mail address provided.
Going to car approx. 45 min-1 hr after receiving PPD & Tdap in Employee Health Services and noted tongue swelling & difference in voice - went to ED believing she was having allergic response - copies of records attached.
Information has been received from a medical assistant referring to unspecified number of male and female patients. No relevant medical history or current conditions were reported. Within the last six month since an unknown date, these patients were vaccinated with GARDASIL (dose, route, lot# and expiration date not reported). Concomitant therapies included MENACTRA and "TDAP". On unknown dates these patients had been getting dizzy, been very pale and "spaced out" after the vaccination of GARDASIL while lying down. No further explanation of "spaced out" was provided. The outcome of the events was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
This spontaneous report as received from a Licensed Practical Nurse refers to an unspecified number of patients. In 2014 an unspecified number of patients received improperly stored PEDVAXHIB (lot #, expiration date and dose unspecified). No symptoms reported. This is one of several reports received from same source. Additional information has been requested.
Expired vaccine administered to patient; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient). On 12-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided  No treatment information was provided   This case was linked to MOD-2021-285598 (Patient Link).
Itching all over-even her girl part-she says Told to go to the ER, call her PCM-as the day has progressed her itching has gotten worse
Significant Shoulder soreness.  Patient also claims that this has never happened before and also confirmed that he believes the injection was done correctly.  Proper placement and depth.
Post zoster vaccination high skin sensitivity from right side of spine following to right side of breast.  Could be painful with slightest touch.  No visual skin changes.  Lasted 4 weeks.
pt recv vax & devel an eruption of greater than 100 lesions, low grade temp & pruritus;
14 year old patient rec'd Fluzone High Dose, no treatment necessary, no adverse reaction.
Bad Headaches - daily since. Migraine size 1st two days. Still having them Abdominal pain - feels like ovary pain Slight Blurred vision -feels like from headache
A healthcare professional reported that a 66 year old female received Pnu-Imune 23 on 5/3/01. Within hours, post vax, the pt developed an injection site reaction characterized by "severe" swelling, redness and pain from her shoulder to her fingertips. The pt was treated with applications of warm compresses. This is 1 of 2 pts from this facility who experienced this event, post vax, of Pnu-Imune 23 (lot 475387).
Patient took Aspirin the morning of the vaccine.   Next day, by night, patient was achy and cramping on upper abdomen.   At around 2am patient woke up and was nauseous.   By 2:15am to 2:30am started throwing up.  Patient had cramps in abdomen and since then a headache.  Diarrhea started on Tuesday. Yesterday had cramps again.  Last night, by evening woke up and vomited again in the morning.  Patient contacted vaccine administrator today and was recommended to follow-up with doctor; appointment scheduled for tomorrow at 1:30pm.   Today patient ate lunch today with no problem, has a little cramping and no diarrhea.  Diarrhea usually starts at nigh when in bed. Patient is at 80% recovery.
a dose of expired Kinrix was administered to a patient.; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received DTPa-IPV (Kinrix) (batch number unknown, expiry date 26th August 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 30th August 2022, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 30th August 2022, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 31-AUG-2022 Reporter's comment: Healthcare Professional (HCP) reported that an expired dose of Kinrix was administered to a patient on day before the reporting day. No details for adverse event, either lot number or patient details were available at the time of chat but the reporter consented to follow up via email. Additional supportive information: The patient had received an expired dose of Kinrix, which led to expired vaccine used.
One week after that shot, all my long hauler symptoms came rushing back including intense, very painful inflammatory flares all over my body. These episodes include a tremendous amount of swelling, ringing ears, fatigue, numbness and widespread pain throughout my back, chest, and limbs.
Shortness of breath; Had a overdose of the Pfizer first dose of the Covid-19 Vaccine; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 19 year-old male patient received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DYSPNOEA (non-serious) with onset 2021, outcome "unknown", described as "Shortness of breath"; OVERDOSE (non-serious) with onset 2021, outcome "unknown", described as "Had a overdose of the Pfizer first dose of the Covid-19 Vaccine".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I got the injection on Tuesday, 4/13/2021. My left arm, the arm I got the injection, immediately started hurting after I got the shot. Starting on Wednesday, I had slight fever, congestion, felt discomfort in my chest, like pressure, and I felt slight discomfort in my right arm. Thursday I woke up with more pain in my right arm, and by 1:30, when I got off work, I had trouble even lifting my right arm. By Friday I was in excruciating pain and unable to move my right arm at all. My right arm is still currently swollen down to my wrist and my fingers on my right hand feel stiff.
Tachycardia, shortness of breath. Occurred while sleeping for about 30-45 minutes.  Was transported by ambulance to hospital.
24 hours after receiving Anthrax #1, member experienced abdominal pain, urinary discomfort, tender lymph nodes, and a rash under armpits, and in groin.  Pain lasted 1 week, rash 3 days.
Patient came out to pharmacy on August 9, 2018 saying that his upper arm has been in pain and the pain has been worsening. We have been in contact with the patient (last 8/17) and he claims the pain still persist and has not been improved. We contacted the manufacture as well and recommended for pain management with Tylenol/Ibuprofen.
Walking difficulty. Injection site inflammation. Injection site tenderness. Injection site redness. Injection site warmth. From initial information received on 26/sep/2003 from a health care professional, regarding an adverse event occurring in the USA, it was reported that a three-year old female patient received her fourth dose of DAPTACEL, lot number C1387AA, administered intra-muscularly in the left anterior thigh on 23/Sep/2003. Two days later,the patient developed a large local reaction, approximately four inches in circumference. The area was red, tender and hot. The patient also experienced some difficulty in walking. No systemic problems reported. At the time of this event, the patient was also taking Keflex and Atarax. The patient's recovery status was not reported.
CHILD GOT A RASH AS AN ALLERGIC REACTION TO TDAP.  HE GOT RASH OF A SIZE OF 11CMX7CM ON SITE OF INJECTION.  DR GAVE HIM SAMPLES OF ZYRTEC TO TAKE TWICE A DAY.
One month after booster dose, Ventricular Tachycardia, decrease in EF to 30% requiring ICU admission.
PT. RECEIVED DAPTCELL VACCINE IN L. DELTOID. AFTER 48 HOURS PT. RETURNED TO OFFICE TO HAVE PPD READ & PARENT STATED INJECTION SITE WAS RED, SLIGHTLY SWOLLEN & WARM TO THE TOUCH.
Patient was not 18 at the time of the vaccine. No adverse effects reported from patient or parent and parent chooses to continue with  2nd dose in series as off-label use.
113 Bivalent doses administered after the BUD to; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to) and NO ADVERSE EVENT (No adverse event) in an adult female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to).    No concomitant medicine were reported. No treatment medicine were reported.   This case was linked to MOD-2022-690921 (Patient Link).
Chills, fever, headache, aches, shooting pains - lasting 3.5 days. Pain around joints and inside bones. It is 3/1/2021 and the symptoms have seemed to subside.
mom states PMD measured redness & swelling in both arms;DTAP given lt deltoid;mom states measurement was 5x 6 1/2cm severely red w/blue center;HIB given rt deltoid mom states measurement was 6x7 1/2cm severely red;
8 hrs after vaccine #2  terrible headache. felt like chisel was hitting head above brow bone.; Injections site extremely sore; Intermittent chills; headache& sore arm; This is a spontaneous report from a non-contactable consumer.   A 71-years-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: not reported), via an unspecified route of administration (at the age of 71 years) as dose 2, single for covid-19 immunization. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 for covid-19 immunization. The patient relevant medical history includes high blood pressure. Patient had no known allergies.  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  The patient concomitant medications were not reported. It was reported that 8 hours after vaccine 2 patient had experienced terrible headache, felt like chisel was hitting head above brow bone, Injections site extremely sore. Headache and sore arm slowly subsided after 24 hrs. Intermittent chills also occurred while experiencing headache. By day 3 felt. No treatment was received in response to the adverse events. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, patient was not tested for COVID-19. The outcome of the events were recovered.   No follow-up attempts are possible. No further information is provided.
pt was in the local Hospital 2 days prior to coming to ED for COVID pneumonia; pt had a positive COVID test on 1/13/22 and 1/25/22; family refused rehab for pt after hospitalization; 2/9/22 pt saw PCP and was found to be extremely weak, dehydrated and malnourished; sent to ED; CXR showed multifocal pneumonia; admitted; AKI; given IV fluids, ABX; G tube placed; pt developed HCAP and sepsis; hypoxia worsened; family did not want "life support tubes"; pt expired due to respiratory failure secondary to bacterial pneumonia
COVID+ 1/18/2023.  Vaccination Status - Moderna x4 Discharge Provider:  MD Primary Care Provider:  MD Admission Date: 1/18/2023 Discharge Date: Jan 29, 2023   Active Hospital Problems   Diagnosis Date Noted POA ? COVID-19 01/18/2023 Yes ? Fall 02/10/2021 Yes ? Atrial fibrillation, persistent (HCC   PRESENTING PROBLEM: Weakness [R53.1] Acute cystitis without hematuria [N30.00] COVID [U07.1] COVID-19 [U07.1]   HOSPITAL COURSE: A 94 y.o. female w/ PMH significant for atrial fib, chronic pain, depression, chronic leg edema and HTN who presented to the ED per EMS on 1/18 after a fall at her apartment.  Patient lives alone in own apartment assisted living facility. Son states patient fell twice on 1/17 at home. He states she was seen by EMS after first fall during day and refused transport to hospital at that time. Patient states she also fell getting up during the night to use bathroom. She recalls feeling mild dizziness after standing up from using bathroom. She denies LOC, thinks she hit posterior head in bathroom. She denies any syncope. She felt she could not stand up on her own from the floor. She hit her med alert button to call EMS. She states she did not experience dizziness during daytime fall on 1/17. She also complains of cough, nasal congestion, rhinorrhea over 4-5 days. She complains of fatigue and generalized weakness over 4 days. She was started on Lasix on 1/3 per PCP, due to leg edema. Patient recently tested positive for COVID as outpatient on home test on 1/17, she took 2 doses of Paxlovid as outpatient on 1/17. She was seen via telephone audio visit with primary care NP due to COVID diagnosis on 1/17.   She was admitted for further medical management.  CT head was without acute abnormalities.  CT cervical spine was negative for acute process.  While in the emergency department, she was given a dose of fosfomycin due to urinalysis showing pyuria.  Patient denied symptoms of dysuria.  She was started on IV remdesivir for treatment of COVID-19.  She was not hypoxic and did not require Decadron.  She received electrolyte replacement as needed.  She was evaluated by PT/OT and subacute rehab was recommended.  Care manager assisted with placement at subacute rehab. First day eligible for transition to facility post-covid was 01/25/2023. CXR done on 1/28 for persistent cough showed right lower/mid-lob PNA however subsequently without intervention cough improved so no further intervention was taken.patient cleared for discharge 1/29, her cough persisted and was causing right-sided chest pain with it, aside from this and her debility she had no complaints. at the time of discharge patient was in good spirits and eager to leave. all questions and concerns addressed, all meds and follow-ups reviewed. she was sent to (facility).
1/9/21-17:15- started having chills, muscle pain. Pain L arm(injection site) 18:00- low grade temp 99.3, muscle pain arms and legs worse Uncomfortable during the entire night (tossing and turning) 1/10/21- 07:30-General malaise(flu like symptoms)- muscle pain-feeling weak T-99 started feeling better during the late afternoon, still with muscle pain , T-98.7
6-7 pts who recvd Engerix-B exp the following events p/1st dose; Gastrointestinal upset; severe back pain; severe muscle pain; mouth blisters;
Terrible rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Terrible rash) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included FEXOFENADINE HYDROCHLORIDE (ALLEGRA) for Seasonal allergy.    On 09-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (Terrible rash). The patient was treated with CORTISONE at an unspecified dose and frequency. At the time of the report, RASH (Terrible rash) outcome was unknown. Not Provided          Treatment details include Cortisone cream 5-day course of steroids   This case was linked to MOD-2021-114598 (Patient Link).
During a review of the  Department of Health's internal records, it was found that there might have been a possible temperature excursion with how the vaccine was stored with our mobile vendor.
This spontaneous report was received from a nurse practitioner and refers to a 13-year-old male patient. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 21-NOV-2018, the patient was vaccinated with the first dose of GARDASIL 9 intramuscular (lot # R003557, expiration date: 20-NOV-2020, dose was not provided) for prevention of human papilloma virus (HPV) and influenza virus vaccine (unspecified) for prophylaxis. On the sam date, immediately afterwards, the patient began shaking. All neurological checks and vital signs were normal. Electrocardiography (EKG) was performed on the same date and revealed sinus arrhythmia, however it was hard to determine if accurate because patient was shaking and result might have been artifact. The patient was sent home with his mother with plans to repeat the EKG in one week. The patient recovered from shaking on the same date after 50-55 minutes. The outcome of sinus arrhythmia was unknown. The relatedness between the events and suspect therapies were not reported.
The patient received her 1st dose of Moderna vaccine at 5:57 pm and headed to the observation area. Approximately in 20 minutes after the vaccination she approached the observation nurse and reported that she was experiencing some rash and itching around her neck. Upon examination moderate hives was noted on the neck and upper chest. The patient stated she usually was having redness around her neck and said she would like to stay longer in the observation for monitoring. Vital signs - BP 125/80, Pulse 72, SatO2 100%. After 15 minutes the redness spread up to the ears and behind the neck and the patient was offered  Benadyl IM. At 6:51 50 mg of Benadryl IM was administered into the left deltoid muscle by RN. The patient stated she did not premedicate before the vaccination. After 15 minutes the patient reported that her itching diminished and the redness on the neck area visually fade away. Vitals - BP 130/80, pulse 92, SatO2 100%
No Adverse event; a dose was administered to a patient after a temperature excursion occurred; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 31-JAN-2022, the patient was vaccinated with a dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, 1 dose, lot #U008315, expiration date: 15-AUG-2023, administered for prophylaxis (strength, and route of administration were not provided) after a temperature excursion occurred. The vaccine underwent a temperature excursion of 0.5 degree Celsius (C) for a period of 168 hours. The vaccine did not undergo previous temperature excursion. The patient did not experience any adverse event.
Anaphalatic Shock - Rash / Hives / redness / heat / inability to communicate / swelling of the throat. Epi pen , Epinephrane in Ambulance, Steroids and Benedryl, overnight stay
Patient developed a 65mm diameter red slightly raised area at injection site. No fever. He was treated with ibuprofen, oral BENADRYL, and topical BENADRYL. Symptoms resolved in 48 hours.
Pale, Short of Breath, Hypoxic, Lethargic within minutes became unresponsive and died.